Allogeneic gamma delta T-cell therapy - bluebird bio/TC BioPharm

Drug Profile

Allogeneic gamma delta T-cell therapy - bluebird bio/TC BioPharm

Alternative Names: Gamma delta CAR T cells; OmnImmune®

Latest Information Update: 12 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TC BioPharm
  • Class Antibacterials; Antineoplastics; Antivirals; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Bacterial infections; Cancer; Viral infections

Most Recent Events

  • 08 Dec 2017 TC Biopharm and bluebird bio entered a collaboration and licensing agreement to advance allogeneic gamma delta T-cell therapy for Cancer, Bacterial infections, Viral infections, Haematological malignancies and Solid tumours
  • 09 Aug 2017 Preclinical trials in Bacterial infections in United Kingdom (Parenteral) (TC BioPharm website, August 2017)
  • 09 Aug 2017 Preclinical trials in Viral infections in United Kingdom (Parenteral) (TC BioPharm website, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top